Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Wnt family member 10A (WNT10A)
- Target
- WNT10A
- Molecular classification
- Secreted signaling protein, Wnt family ligand, Receptor ligand (for frizzled receptors)
01
Overview
Wnt family member 10A (WNT10A) is a secreted signaling protein that acts as a ligand for frizzled family receptors and is essential for normal development and maintenance of multiple ectodermal tissues, including skin, hair, nails, teeth, and sweat glands. WNT10A mediates its effects through the canonical Wnt/beta-catenin pathway, influencing cell fate, proliferation, and tissue differentiation during embryogenesis. Mutations in WNT10A cause a spectrum of ectodermal dysplasias and tooth agenesis, while overexpression is linked to oncogenesis, especially within certain hematological and epithelial cancers. As a therapeutic target, WNT10A’s pathway is implicated in cancer, regenerative medicine, and congenital disorders, but safety concerns arise due to its broad developmental roles[1][2][3][5][7][8].
- Other names
- Protein Wnt-10aWNT10AECTD16OODDSSPSSTHAG4protein Wnt-10a precursorwingless-type MMTV integration site family, member 10A
02
Mechanism of action
Inhibition or activation of Wnt/beta-catenin signaling by modulating WNT10A ligand-receptor interaction to affect downstream gene transcription
03
Biological functions
Signal transduction (Wnt/beta-catenin pathway)Regulation of cell fateEmbryonic patterningEctodermal developmentDevelopment of skin, hair, nails, teeth, and sweat glandsCell proliferation (basal cells of tongue papillae, plantar epithelium, sweat ducts)
04
Disease associations
Cancer (oncogenesis, especially via Wnt/beta-catenin signaling)Ectodermal dysplasias (hypohidrotic ectodermal dysplasia, Schopf–Schulz–Passarge syndrome, odonto-onycho-dermal dysplasia)Tooth agenesis (nonsyndromic and syndromic)Keratoconus (possible association)
05
Safety considerations
Inhibition of WNT10A or pathway may disrupt ectodermal tissue development, leading to side effects such as hair, skin, nail, tooth, and sweat gland abnormalitiesPathway modulation may impact stem cell regulation and carcinogenesis risk
06
Interacting drugs
PRI-724
1 more in the full profile.
07
Biomarkers
Mutations in WNT10A are used as biomarkers for hypohidrotic ectodermal dysplasia, tooth agenesis, Schopf–Schulz–Passarge syndrome, and odonto-onycho-dermal dysplasiaOverexpression in cancer cell lines (e.g., promyelocytic leukemia, Burkitt's lymphoma, colorectal cancer) is a biomarker for Wnt pathway activation and possibly oncogenic risk
Beyond the preview
Go deeper on Wnt family member 10A (WNT10A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wnt family member 10A (WNT10A).